Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul Study

American Heart Journal

Volumn 163, Issue 2, 2012, Pages 274-279

  Dubin, Ruth ^a   Li, Yongmei ^b   Ix, Joachim H ^c   Shlipak, Michael G ^a,b   Whooley, Mary ^a,b   Peralta, Carmen A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; PENTRAXIN 3;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE;

ACUTE-PHASE PROTEINS; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SERUM AMYLOID P-COMPONENT; SURVIVAL RATE; UNITED STATES;

EID: 84863068974     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.11.007     Document Type: Article

References (27)

1. R. Latini, A.P. Maggioni, and G. Peri Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction Circulation 110 2004 2349 2354 (Pubitemid 39407338)
2. S. Matsui, J. Ishii, and F. Kitagawa Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction Atherosclerosis 210 2010 220 225
3. N.S. Jenny, A.M. Arnold, and L.H. Kuller Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 29 2009 594 599
4. M.S. Rolph, S. Zimmer, and B. Bottazzi Production of the long pentraxin PTX3 in advanced atherosclerotic plaques Arterioscler Thromb Vasc Biol 22 2002 e10 e14
5. J. Matsubara, S. Sugiyama, and T. Nozaki Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction J Am Coll Cardiol 57 2011 861 869
6. R. Dubin, M. Shlipak, and Y. Li Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis Nephrol Dial Transplant 2010
7. M. Tong, J.J. Carrero, and A.R. Qureshi Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality Clin J Am Soc Nephrol 2 2007 889 897
8. M.C. Foster, M.J. Keyes, and M.G. Larson Relations of measures of endothelial function and kidney disease: the Framingham Heart Study Am J Kidney Dis 52 2008 859 867
9. M.I. Yilmaz, A. Sonmez, and A. Ortiz Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes Clin J Am Soc Nephrol 6 2011 785 792
10. J. Coresh, B. Astor, and M.J. Sarnak Evidence for increased cardiovascular disease risk in patients with chronic kidney disease Curr Opin Nephrol Hypertens 13 2004 73 81 (Pubitemid 39069902)
11. J.H. Ix, M.G. Shlipak, and G.M. Chertow Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study Circulation 115 2007 173 179 (Pubitemid 46105715)
12. M.G. Shlipak, R. Katz, and M.J. Sarnak Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease Ann Intern Med 145 2006 237 246 (Pubitemid 46768607)
13. M.G. Shlipak, M.J. Sarnak, and R. Katz Cystatin C and the risk of death and cardiovascular events among elderly persons N Engl J Med 352 2005 2049 2060 (Pubitemid 40664306)
14. M.G. Shlipak, C.L. Wassel Fyr, and G.M. Chertow Cystatin C and mortality risk in the elderly: the health, aging, and body composition study J Am Soc Nephrol 17 2006 254 261
15. B. Ruo, J.S. Rumsfeld, and M.A. Hlatky Depressive symptoms and health-related quality of life: the Heart and Soul Study JAMA 290 2003 215 221 (Pubitemid 37430060)
16. B.A. Perkins, R.G. Nelson, and B.E. Ostrander Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study J Am Soc Nephrol: JASN 16 2005 1404 1412 (Pubitemid 41716524)
17. L.A. Stevens, J. Coresh, and C.H. Schmid Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD Am J Kidney Dis 51 2008 395 406 (Pubitemid 351273480)
18. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
19. M.S. Beattie, M.G. Shlipak, and H. Liu C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study Circulation 107 2003 245 250 (Pubitemid 36135219)
20. R.V. Luepker, F.S. Apple, and R.H. Christenson Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute Circulation 108 2003 2543 2549
21. M.A. Whooley, P. de Jonge, and E. Vittinghoff Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease JAMA 300 2008 2379 2388
22. M.M. Redfield, S.J. Jacobsen, and J.C. Burnett Jr. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic JAMA 289 2003 194 202 (Pubitemid 36068707)
23. C. Garlanda, B. Bottazzi, and F. Moalli Pentraxins and atherosclerosis: the role of PTX3 Curr Pharm Des 17 2011 38 46
24. A. Inforzato, C. Baldock, and T.A. Jowitt The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2 J Biol Chem 285 2010 17681 17692
25. M. Camozzi, S. Zacchigna, and M. Rusnati Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo Arterioscler Thromb Vasc Biol 25 2005 1837 1842 (Pubitemid 41243451)
26. G.D. Norata, P. Marchesi, and V.K. Pulakazhi Venu Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis Circulation 120 2009 699 708
27. M. Salio, S. Chimenti, and N. De Angelis Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction Circulation 117 2008 1055 1064